<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137693">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686581</url>
  </required_header>
  <id_info>
    <org_study_id>MAF/AGN/NS/CM/002</org_study_id>
    <nct_id>NCT01686581</nct_id>
  </id_info>
  <brief_title>An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®)
      as prescribed by the physician for headache prophylaxis in adults with chronic migraine.
      All treatment decisions lie with the physician.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Healthcare Resource Utilization Using a Patient Questionnaire</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>EuroQol Group EQ-5D Questionnaire Score</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Frequency</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Satisfaction Using a 4-Point Scale</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Specific Quality of Life Questionnaire (MSQ) Score</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Patients with Chronic Migraine Prescribed BOTOX®</arm_group_label>
    <description>Onabotulinumtoxin A (BOTOX®) administered according to physician prescription; all treatment decisions lie with the physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onabotulinumtoxin A</intervention_name>
    <description>Onabotulinumtoxin A (BOTOX®) administered according to physician prescription; all treatment decisions lie with the physician.</description>
    <arm_group_label>Patients with Chronic Migraine Prescribed BOTOX®</arm_group_label>
    <other_name>BOTOX®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic migraine prescribed BOTOX® for the prophylaxis of headaches
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prescribed BOTOX® for the prophylaxis of headaches

        Exclusion Criteria:

          -  Received treatment with any botulinum toxin Type A serotype in the last 26 weeks

          -  Current participation in Allergan's Botox Chronic Migraine Post-Authorisation Safety
             Study (protocol 191622-110)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Anlaby, Hull</city>
        <state>East Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
